Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Could big pharma buy out much of the biotech industry? Yes, according to analysts. But that’s not likely to happen anytime soon.
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
Orion announced that it will be focusing on pain and oncology going forward. As a result, 32 working professionals within the company will be terminated, although six of those will be offered different positions.
Oxurion NV’s proposed drug for diabetic macular edema failed to demonstrate efficacy on key endpoints based on top line results from its Phase II trial.
Some cytokines can stimulate the immune system, while others slow it down. Here’s a look at the latest news on cytokine data and therapy developments.
LogicBio Therapeutics has received the green light to continue dosing participants in its Phase I/II Sunrise trial, following a clinical hold placed by the FDA due to adverse events in pediatric patients.
Athira Pharma announced the duration of its open-label study of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s Disease (AD) has been increased from six months to eighteen months.
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
According to a survey by CareerBuilder, 23% of hiring managers spend less than 30 seconds reading a resume. Make the most of those seconds with these five tips to make your resume stand out.
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
Today’s announcement from Seagen’s board of directors included difficult news regarding Clay Siegall, Ph.D. Until today, Siegall served as Seagen’s President, CEO and Chairman.
Complicated bone fractures take a long while to heal. Bone Therapeutics S.A. is developing a cell therapy product that speeds bone regeneration and just may solve that problem.